Baxter Comprehensive Income 2010-2024 | BAX
Baxter comprehensive income from 2010 to 2024. Comprehensive income can be defined as the change in net assets of a business enterprise during a period from transactions and other events and circumstances from nonowner sources. It includes all changes in equity during a period except those resulting from investments by owners and distributions to owners.
- Baxter comprehensive income for the quarter ending September 30, 2024 was $-3.647B, a 1.86% decline year-over-year.
- Baxter comprehensive income for 2023 was $-3.554B, a 7.28% decline from 2022.
- Baxter comprehensive income for 2022 was $-3.833B, a 13.4% increase from 2021.
- Baxter comprehensive income for 2021 was $-3.38B, a 1.99% increase from 2020.
| Baxter Annual Comprehensive Income (Millions of US $) |
|
|---|---|
| 2023 | $-3,554 |
| 2022 | $-3,833 |
| 2021 | $-3,380 |
| 2020 | $-3,314 |
| 2019 | $-3,710 |
| 2018 | $-3,823 |
| 2017 | $-4,001 |
| 2016 | $-4,556 |
| 2015 | $224 |
| 2014 | $-3,650 |
| 2013 | $-1,976 |
| 2012 | $-2,810 |
| 2011 | $-2,591 |
| 2010 | $-2,139 |
| 2009 | $-1,777 |
| Baxter Quarterly Comprehensive Income (Millions of US $) |
|
|---|---|
| 2024-09-30 | $-3,647 |
| 2024-06-30 | $-3,828 |
| 2024-03-31 | $-3,722 |
| 2023-12-31 | $-3,554 |
| 2023-09-30 | $-3,716 |
| 2023-06-30 | $-3,814 |
| 2023-03-31 | $-3,739 |
| 2022-12-31 | $-3,833 |
| 2022-09-30 | $-4,054 |
| 2022-06-30 | $-3,767 |
| 2022-03-31 | $-3,387 |
| 2021-12-31 | $-3,380 |
| 2021-09-30 | $-3,482 |
| 2021-06-30 | $-3,376 |
| 2021-03-31 | $-3,480 |
| 2020-12-31 | $-3,314 |
| 2020-09-30 | $-3,839 |
| 2020-06-30 | $-3,988 |
| 2020-03-31 | $-4,177 |
| 2019-12-31 | $-3,710 |
| 2019-09-30 | $-4,288 |
| 2019-06-30 | $-4,639 |
| 2019-03-31 | $-4,562 |
| 2018-12-31 | $-3,823 |
| 2018-09-30 | $-4,239 |
| 2018-06-30 | $-4,199 |
| 2018-03-31 | $-3,876 |
| 2017-12-31 | $-4,001 |
| 2017-09-30 | $-3,994 |
| 2017-06-30 | $-4,176 |
| 2017-03-31 | $-4,418 |
| 2016-12-31 | $-4,556 |
| 2016-09-30 | $-4,172 |
| 2016-06-30 | $-4,204 |
| 2016-03-31 | $-3,035 |
| 2015-12-31 | $224 |
| 2015-09-30 | $-617 |
| 2015-06-30 | $-4,146 |
| 2015-03-31 | $-4,709 |
| 2014-12-31 | $-3,650 |
| 2014-09-30 | $-2,654 |
| 2014-06-30 | $-2,145 |
| 2014-03-31 | $-1,946 |
| 2013-12-31 | $-1,976 |
| 2013-09-30 | $-2,600 |
| 2013-06-30 | $-2,765 |
| 2013-03-31 | $-2,757 |
| 2012-12-31 | $-2,810 |
| 2012-09-30 | $-2,549 |
| 2012-06-30 | $-2,737 |
| 2012-03-31 | $-2,449 |
| 2011-12-31 | $-2,591 |
| 2011-09-30 | $-2,049 |
| 2011-06-30 | $-1,772 |
| 2011-03-31 | $-1,875 |
| 2010-12-31 | $-2,139 |
| 2010-09-30 | $-1,971 |
| 2010-06-30 | $-2,348 |
| 2010-03-31 | $-2,033 |
| 2009-12-31 | $-1,777 |
| 2009-09-30 | $-1,609 |
| 2009-06-30 | $-1,752 |
| 2009-03-31 | $-1,977 |
| Sector | Industry | Market Cap | Revenue |
|---|---|---|---|
| Medical | Medical Products Manufacturing | $16.604B | $14.813B |
| Baxter International Inc. is a global medical technology company. The company consists of renal and hospital products, providing items such as kidney-dialysis equipment, infusion pumps, and intravenous (IV) solutions. Baxter has been reporting through six revenue segments. Renal Care, Medication Delivery, Pharmaceuticals, Clinical Nutrition, Advanced Surgery, Acute Therapies and Other. Baxter's Renal segment primarily consists of Peritoneal Dialysis (PD) and Hemodialysis (HD) therapies. The portfolio addresses the needs of patients with kidney failure or kidney disease, and their healthcare providers, with a comprehensive range of therapeutic options across home, in-center, and hospital settings for better individualized care. | |||
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Abbott Laboratories (ABT) | United States | $203.157B | 25.91 |
| Stryker (SYK) | United States | $148.171B | 33.39 |
| Boston Scientific (BSX) | United States | $133.131B | 38.28 |
| EssilorLuxottica (ESLOY) | France | $113.461B | 0.00 |
| Medtronic (MDT) | Ireland | $109.010B | 16.19 |
| Haleon (HLN) | United Kingdom | $42.913B | 27.88 |
| Lonza Group Ag (LZAGY) | Switzerland | $42.122B | 0.00 |
| GE HealthCare Technologies (GEHC) | United States | $37.701B | 19.56 |
| ResMed (RMD) | United States | $34.955B | 28.72 |
| Terumo (TRUMY) | Japan | $29.203B | 41.24 |
| Koninklijke Philips (PHG) | Netherlands | $24.410B | 18.68 |
| Zimmer Biomet Holdings (ZBH) | United States | $22.087B | 14.06 |
| Insulet (PODD) | United States | $18.377B | 73.18 |
| Smith & Nephew SNATS (SNN) | United Kingdom | $11.153B | 0.00 |
| BellRing Brands (BRBR) | United States | $9.468B | 37.96 |
| Bio-Rad Laboratories (BIO) | United States | $8.977B | 30.51 |
| Demant (WILYY) | Denmark | $8.342B | 0.00 |
| Lantheus Holdings (LNTH) | United States | $5.523B | 12.83 |
| TG Therapeutics (TGTX) | United States | $4.720B | 0.00 |
| Haemonetics (HAE) | United States | $4.260B | 20.79 |
| ICU Medical (ICUI) | United States | $4.155B | 39.56 |
| Prestige Consumer Healthcare (PBH) | United States | $4.074B | 20.26 |
| Perrigo (PRGO) | Ireland | $3.716B | 10.94 |
| Envista Holdings (NVST) | United States | $3.487B | 25.97 |
| Neogen (NEOG) | United States | $3.270B | 37.72 |
| Agios Pharmaceuticals (AGIO) | United States | $3.103B | 0.00 |
| Shandong Weigao Medical Polymer (SHWGF) | China | $3.010B | 0.00 |
| GN Store Nord (GNNDY) | Denmark | $2.789B | 17.89 |
| QuidelOrtho (QDEL) | United States | $2.595B | 16.70 |
| Warby Parker (WRBY) | United States | $2.344B | 0.00 |
| LeMaitre Vascular (LMAT) | United States | $2.332B | 56.69 |
| Green Thumb Industries (GTBIF) | United States | $1.964B | 34.37 |
| AtriCure (ATRC) | United States | $1.772B | 0.00 |
| InMode (INMD) | Israel | $1.487B | 8.94 |
| Curaleaf Holdings (CURLF) | Canada | $1.348B | 0.00 |
| AdaptHealth (AHCO) | United States | $1.311B | 9.37 |
| Maravai LifeSciences Holdings (MRVI) | United States | $1.168B | 0.00 |
| BioLife Solutions (BLFS) | United States | $1.041B | 0.00 |
| Phibro Animal Health (PAHC) | United States | $0.962B | 16.96 |
| Owens & Minor (OMI) | United States | $0.957B | 7.48 |
| CeriBell (CBLL) | United States | $0.916B | 0.00 |
| National Vision Holdings (EYE) | United States | $0.888B | 29.68 |
| Capricor Therapeutics (CAPR) | United States | $0.839B | 0.00 |
| Evolus (EOLS) | United States | $0.785B | 0.00 |
| Verano Holdings (VRNOF) | United States | $0.608B | 0.00 |
| Cresco Labs (CRLBF) | United States | $0.596B | 0.00 |
| VAREX IMAGING (VREX) | United States | $0.596B | 26.47 |
| Surmodics (SRDX) | United States | $0.559B | 0.00 |
| Quanterix (QTRX) | United States | $0.424B | 0.00 |
| Canopy Growth (CGC) | Canada | $0.404B | 0.00 |
| Valneva SE (VALN) | France | $0.370B | 0.00 |
| ZimVie (ZIMV) | United States | $0.363B | 30.63 |
| Omeros (OMER) | United States | $0.349B | 0.00 |
| Viemed Healthcare (VMD) | United States | $0.335B | 31.89 |
| Biote (BTMD) | United States | $0.330B | 7.25 |
| Sanara MedTech (SMTI) | United States | $0.323B | 0.00 |
| Cerus (CERS) | United States | $0.312B | 0.00 |
| OraSure Technologies (OSUR) | United States | $0.288B | 19.30 |
| Zynex (ZYXI) | United States | $0.249B | 52.13 |
| TerrAscend (TSNDF) | Canada | $0.243B | 0.00 |
| Aurora Cannabis (ACB) | Canada | $0.229B | 0.00 |
| Utah Medical Products (UTMD) | United States | $0.219B | 15.15 |
| MacroGenics (MGNX) | United States | $0.218B | 0.00 |
| High Tide (HITI) | Canada | $0.215B | 89.00 |
| Sanuwave Health (SNWV) | United States | $0.195B | 2.74 |
| Jin Medical (ZJYL) | China | $0.188B | 0.00 |
| Zevia PBC (ZVIA) | United States | $0.162B | 0.00 |
| Brainsway (BWAY) | Israel | $0.161B | 96.70 |
| Organigram Holdings (OGI) | Canada | $0.158B | 0.00 |
| FitLife Brands (FTLF) | United States | $0.143B | 17.98 |
| TriSalus Life Sciences (TLSI) | United States | $0.126B | 0.00 |
| Quipt Home Medical (QIPT) | United States | $0.106B | 0.00 |
| Fonar (FONR) | United States | $0.093B | 10.54 |
| Oramed Pharmaceuticals (ORMP) | United States | $0.093B | 23.00 |
| Veru (VERU) | United States | $0.092B | 0.00 |
| Ayr Wellness (AYRWF) | United States | $0.082B | 0.00 |
| Rockwell Medical (RMTI) | United States | $0.080B | 41.50 |
| Modular Medical (MODD) | United States | $0.073B | 0.00 |
| Jushi Holdings (JUSHF) | United States | $0.070B | 0.00 |
| Cellectar Biosciences (CLRB) | United States | $0.066B | 0.00 |
| InterCure (INCR) | Israel | $0.063B | 0.00 |
| Exagen (XGN) | United States | $0.062B | 0.00 |
| MariMed (MRMD) | United States | $0.059B | 0.00 |
| Safety Shot (SHOT) | United States | $0.056B | 0.00 |
| Cytosorbents (CTSO) | United States | $0.052B | 0.00 |
| Apyx Medical (APYX) | United States | $0.048B | 0.00 |
| ImmuCell (ICCC) | United States | $0.032B | 0.00 |
| Allurion Technologies (ALUR) | United States | $0.026B | 0.00 |
| Flora Growth (FLGC) | United States | $0.018B | 0.00 |
| Nephros (NEPH) | United States | $0.016B | 0.00 |
| Meihua Medical Technologies (MHUA) | China | $0.013B | 0.00 |
| Innovative Eyewear (LUCY) | United States | $0.011B | 0.00 |
| Trinity Biotech (TRIB) | Ireland | $0.010B | 0.00 |
| NeuroMetrix (NURO) | United States | $0.008B | 0.00 |
| IM Cannabis (IMCC) | Canada | $0.006B | 0.00 |
| Agape ATP (ATPC) | $0.006B | 0.00 | |
| Leafly Holdings (LFLY) | United States | $0.005B | 0.00 |
| Sharps Technology (STSS) | United States | $0.005B | 0.00 |
| Akanda (AKAN) | United Kingdom | $0.002B | 0.00 |
| GlucoTrack (GCTK) | United States | $0.001B | 0.00 |
| Senestech (SNES) | United States | $0.001B | 0.00 |
| InVivo Therapeutics Holdings (NVIVQ) | United States | $0.001B | 0.00 |
| United-Guardian (UG) | United States | $0.000B | 13.17 |
| SNDL (SNDL) | Canada | $0.000B | 0.00 |